Varma Sandeep R, Sivaprakasam Thiyagarajan O, Arumugam Ilavarasu, Dilip N, Raghuraman M, Pavan K B, Rafiq Mohammed, Paramesh Rangesh
Department of Cell Biology, Discovery Sciences Group, Research and Development Centre, The Himalaya Drug Company, Makali, Bangalore 562 162, India.
Analytical Development, Research and Development Centre, The Himalaya Drug Company, Makali, Bangalore 562 162, India.
J Tradit Complement Med. 2018 Jan 17;9(1):5-14. doi: 10.1016/j.jtcme.2017.06.012. eCollection 2019 Jan.
Virgin coconut oil (VCO) has been traditionally used as moisturizer since centuries by people in the tropical region. Clinical studies have revealed that VCO improves the symptoms of skin disorders by moisturizing and soothing the skin. However, the mechanistic action of VCO and its benefits on skin has not been elucidated . The cytotoxicity (CTC) of VCO was 706.53 ± 2.1 and 787.15 ± 1.1 μg/mL in THP-1 (Human monocytes) and HaCaT (Human keratinocytes) cells respectively. VCO inhibited TNF-α (62.34 ± 3.2 %), IFN-γ (42.66 ± 2.9 %), IL-6 (52.07 ± 2.0 %), IL-8 (53.98 ± 1.8 %) and IL-5 (51.57 ± 2.6 %) respectively in THP-1 cells. Involucrin (INV) and filaggrin (FLG) content increased by 47.53 ± 2.1 % and 40.45 ± 1.2 % respectively in HaCaT cells. VCO increased the expression of Aquaporin-3 (AQP3), involucrin (INV) and filaggrin (FLG) and showed moderate UV protection in HaCaT cells. skin irritation studies in Reconstructed human epidermis (RHE) and NIH3T3 cells showed that VCO is a non skin irritant (IC > 1000 μg/mL) and non phototoxic (PIF < 2). Our study demonstrated the anti inflammatory activity of VCO by suppressing inflammatory markers and protecting the skin by enhancing skin barrier function. This is the first report on anti-inflammatory and skin protective benefits of VCO . Overall, the results warrant the use of VCO in skin care formulations.
几个世纪以来,热带地区的人们一直将初榨椰子油(VCO)传统用作保湿剂。临床研究表明,VCO通过滋润和舒缓皮肤来改善皮肤疾病的症状。然而,VCO的作用机制及其对皮肤的益处尚未阐明。VCO在THP-1(人单核细胞)和HaCaT(人角质形成细胞)细胞中的细胞毒性(CTC)分别为706.53±2.1和787.15±1.1μg/mL。VCO在THP-1细胞中分别抑制肿瘤坏死因子-α(TNF-α,62.34±3.2%)、干扰素-γ(IFN-γ,42.66±2.9%)、白细胞介素-6(IL-6,52.07±2.0%)、白细胞介素-8(IL-8,53.98±1.8%)和白细胞介素-5(IL-5,51.57±2.6%)。在HaCaT细胞中,兜甲蛋白(INV)和丝聚合蛋白(FLG)含量分别增加了47.53±2.1%和40.45±1.2%。VCO增加了水通道蛋白-3(AQP3)、兜甲蛋白(INV)和丝聚合蛋白(FLG)的表达,并在HaCaT细胞中表现出适度的紫外线防护作用。在重组人表皮(RHE)和NIH3T3细胞中的皮肤刺激性研究表明,VCO是一种非皮肤刺激性物质(IC>1000μg/mL)且无光毒性(PIF<2)。我们的研究通过抑制炎症标志物证明了VCO的抗炎活性,并通过增强皮肤屏障功能来保护皮肤。这是关于VCO抗炎和皮肤保护益处的首次报道。总体而言,这些结果证明VCO可用于皮肤护理配方。